CME/CE Podcast: Shifting Targets? Decoding and Discussing PAH Guidelines

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/decoding-and-discussing-pah-guidelines-8896Featuring faculty Ioana Preston, MD, moderated by Corinne R. Young, MSN, FNP-C, FCCPSummaryIn this episode of NACE Clinical Highlights, Dr. Ioana Preston joins NP Corinne Young to discuss the diagnosis and treatment of pulmonary arterial hypertension (PAH). They dive into the importance of ruling out other groups of pulmonary hypertension and highlight the role of VQ scans in diagnosing chronic clots. The significance of right heart catheterization in confirming the diagnosis and guiding treatment decisions is emphasized. The discussion also covers risk stratification and the benefits of dual upfront therapy with oral drugs for most group one PAH patients, as well as risk stratification-based follow-up management. Finally, Dr. Preston provides insights into upcoming advancements in therapeutic options.Learning ObjectivesUpon completion of this activity, learners should be able to:Identify patients with PAH, utilizing updated definitions and diagnostic evaluationsInitiate therapy for patients with PAH based on currently available guidelinesTransition between therapies in patients with PAH based on risk stratification and guideline- and goal-directed therapyThis activity is accredited for CME/CE Credit.Provided by the National Association for Continuing Education in partnership with the Association for Pulmonary Advanced Practice Providers.The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).Summary of Individual DisclosuresDr. Preston has disclosed the following financial relationships:Consultant: Aerovate, Altavant, Gossamer, Janssen, Liquidia, Merck, Respira, United TherapeuticsAdvisor: Aerovate, Altavant, Gossamer, Janssen, Liquidia, Merck, Respira, United TherapeuticsContracted Research: Janssen, Merck, United TherapeuticsAll her disclosures are related to pulmonary hypertension.Ms. Young has disclosed the following financial relationships:Advisor: AstraZeneca (Asthma), Takeda (Alpha1)Speaker: Griffols (AAT)AAT: alpha-1 antitrypsinAll of the relevant financial relationships listed for these individuals have been mitigated.Faculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.Disclosure of Commercial SupportThis presentation is supported by an educational grant from Merck Sharp & Dohme Corp.Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.